Westfield Capital Management
RCKT icon

Westfield Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Westfield Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,820,701
Closed -$32.2M – 268
2025
Q1 		$32.2M Buy
4,820,701
+106,091
+2% +$1.05M 0.16% 161
2024
Q4 		$59.3M Buy
4,714,610
+220,777
+5% +$3.32M 0.26% 124
2024
Q3 		$83M Buy
4,493,833
+165,911
+4% +$3.4M 0.38% 84
2024
Q2 		$93.2M Buy
4,327,922
+343,892
+9% +$7.9M 0.46% 61
2024
Q1 		$107M Buy
3,984,030
+42,171
+1% +$1.2M 0.56% 47
2023
Q4 		$118M Sell
3,941,859
-252,137
-6% -$5.56M 0.69% 31
2023
Q3 		$85.9M Buy
4,193,996
+538,209
+15% +$9.78M 0.59% 52
2023
Q2 		$72.6M Buy
3,655,787
+419,879
+13% +$8.48M 0.46% 83
2023
Q1 		$55.4M Buy
3,235,908
+330,353
+11% +$6.47M 0.39% 101
2022
Q4 		$56.9M Buy
2,905,555
+252,353
+10% +$4.65M 0.44% 89
2022
Q3 		$42.3M Sell
2,653,202
-700,191
-21% -$10.9M 0.34% 117
2022
Q2 		$46.1M Buy
3,353,393
+1,159,668
+53% +$13.8M 0.36% 98
2022
Q1 		$34.8M Buy
2,193,725
+155,734
+8% +$2.69M 0.22% 137
2021
Q4 		$44.5M Buy
2,037,991
+11,510
+0.6% +$314K 0.26% 124
2021
Q3 		$60.6M Sell
2,026,481
-50,614
-2% -$1.84M 0.37% 103
2021
Q2 		$92M Buy
2,077,095
+413,443
+25% +$18M 0.55% 60
2021
Q1 		$73.8M Buy
1,663,652
+68,671
+4% +$3.77M 0.46% 75
2020
Q4 		$87.5M Buy
1,594,981
+96,488
+6% +$3.52M 0.52% 67
2020
Q3 		$34.3M Sell
1,498,493
-213,008
-12% -$5.25M 0.22% 131
2020
Q2 		$35.8M Buy
1,711,501
+30,067
+2% +$542K 0.25% 122
2020
Q1 		$23.5M Buy
1,681,434
+883,838
+111% +$17.5M 0.21% 127
2019
Q4 		$18.2M Buy
797,596
+11,482
+1% +$192K 0.13% 169
2019
Q3 		$9.16M Buy
786,114
+221,982
+39% +$2.75M 0.07% 188
2019
Q2 		$8.46M Buy
+564,132
New +$9.84M 0.06% 197
2018
Q4 		– Sell
-14,900
Closed -$367K – 265
2018
Q3 		$367K Buy
+14,900
New +$323K ﹤0.01% 242

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Westfield Capital Management's RCKT Position: Q2 2025 in Review

Westfield Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 4,820,701 shares — an estimated $32.2M sold.

Westfield Capital Management first reported a position in RCKT in Q3 2018 and held it in 25 quarters. The position peaked at $118M in Q4 2023. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Westfield Capital Management reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Westfield Capital Management sold 4,820,701 Rocket Pharmaceuticals shares in Q2 2025, an estimated $32.2M.
  • Westfield Capital Management first reported a position in Rocket Pharmaceuticals in Q3 2018 and held it in 25 quarters.
  • Westfield Capital Management's Rocket Pharmaceuticals position peaked at $118M in Q4 2023.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Westfield Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.